Hopp til innhold
NHI.no
Annonse

Prognose

Innhold i artikkelen

Prognosen er god for de som klarer å gjennomføre en god blodsukkerkontroll med HbA1c-verdier på ca. 7,0 prosent.

Prognosen er bekymringsfull ved ubehandlet og dårlig regulert diabetes - det kan føre til redusert syn og i noen tilfeller blindhet. Øyekomplikasjoner ved diabetes er årsaken til nesten ett av fire tilfeller med blindhet i den vestlige verden. Spesifikk laserbehandling av retina og vitrektomi har bedret behandlingsmulighetene og kan redusere diabetesrelatert blindhet med minst 60 prosent. Langtidsoppfølging av opererte i en studie viste at det var ingen tilfeller av alvorlig synstap og moderat synstap ble påvist hos 20 prosent.

Annonse

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Diabetisk retinopati . Referanselisten for dette dokumentet vises nedenfor

  1. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy. A systematic review. JAMA 2007; 298: 902-16. PubMed
  2. Bek T. Øjenkomplikationer ved type 2-diabetes. Ugeskr Læger 2012; 174: 2147. Ugeskrift for Læger
  3. Åsvold BO, Espeland K, Bjørgaas MR, Grill V. Redusert forekomst av proliferativ retinopati ved type 1-diabetes. Tidsskr Nor Legeforen 2011; 131: 17-9. doi:10.4045/tidsskr.09.0490 DOI
  4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169:1307. PubMed
  5. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008; 337: a918. PubMed
  6. Ryan ME, Rajalakshmi R, Prathiba V, et al. Comparison among methods of retinopathy assessment (CAMRA) study. Smartphone, nonmydriatic, and mydriatic photography. Ophtalmology. Published Online: July 15, 2015 . doi:http://dx.doi.org/10.1016/j.ophtha.2015.06.011
  7. Helsedirektoratet. Nasjonale faglig retningslinje for diabetes. Oslo; Helsedirektoratet 2016 helsedirektoratet.no
  8. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44. PubMed
  9. Virk SA, Donaghue KC, Wong TY, Craig ME. Interventions for diabetic retinopathy in type 1 diabetes: Systematic review and meta-analysis. Am J of Ophtalmology, published online July 22, 2015 . doi:http://dx.doi.org/10.1016/j.ajo.2015.07.024
  10. Olsen BS, Sjølie A, Hougaard P, et al, Danish Study Group of Diabetes in Childhood. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes: risk markers for the development of retinopathy, nephropathy and neuropathy. J Diabetes Complications 2000; 14: 295-300. PubMed
  11. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-9. New England Journal of Medicine
  12. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(suppl 2): 21-29.
  13. The DCCT/EDIC Research Group. Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes. N Engl J Med 2015; 372: 1722-33. doi:10.1056/NEJMoa1409463 DOI
  14. Do DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathi. Cochrane Database Syst Rev 2015; 1: CD006127. doi:10.1002/14651858.CD006127.pub2 DOI
  15. Chaturvedi N, Porta M, Klein R et al, for the DIRECT programme study group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402. PubMed
  16. van Leiden HA, Dekker JM, Moll AC, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study. Diabetes Care 2002; 25: 1320-5. PubMed
  17. Klein R, Sharrett AR, Klein BE, et al, ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology 2002; 109: 1225-34. PubMed
  18. Nguyen QD, Shah SM, Heier JS et al, READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the Macula in diabetes (READ-2) study. Ophthalmology 2009; 116: 2175-81. PubMed
  19. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis. Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No.: CD007419. DOI: 10.1002/14651858.CD007419.pub6. The Cochrane Library
  20. Gardlik R, Fusekova I. Pharmacologic therapy for diabetic retinopathy. Semin Ophthalmol. 2015 ; 30(4): 252-63. pmid:24571780 PubMed
  21. Das A, Stroud S, Mehta A, Rangasamy S. New treatments for diabetic retinopathy. Diabetes Obes Metab. 2015;17:219-30. pmid:25160598 PubMed
  22. The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med 2015; 372: 1193-1203. doi:10.1056/NEJMoa1414264 DOI
  23. Evans JR, Michelessi M, Virgili G. Laser photocoagulation for proliferative diabetic retinopathy. Cochrane Database of Syst Rev 2014; 11: CD011234. doi:10.1002/14651858.CD011234.pub2 DOI
  24. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2015 Aug 7;8:CD008214. doi: 10.1002/14651858.CD008214.pub2. DOI
  25. Sjølie AK, Klein R, Porta M et al, for the DIRECT programme study group.. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-93. PubMed
  26. Kohner EM. Aspirin for diabetic retinopathy. BMJ 2003; 327: 1060-1. PubMed
  27. Massin P, Audren F, Haouchine B, et al :Intravitreal Triamcinolone Acetonide for Diabetic Diffuse Macular Edema: Preliminary Results of a Prospective Controlled Trial. Ophthalmology. 2004;111(2):218-224. PubMed
  28. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006; 84: 624-30. PubMed
  29. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006; 22: 200-7. PubMed
  30. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113: 1533-8. PubMed
  31. Sala-Vila A, Díaz-López A, Valls-Pedret C, et al. Dietary marine ω-3 fatty acids and incidente sight-threatening retinopathy in middle-aged and older individuals with type 2 diabetes. Prospective investigation from the PREDIMED trial. JAMA Ophtalmol 2016. doi:10.1001/jamaophthalmol.2016.2906 DOI
  32. Grauslund J. Treatment of sight-threatening diabetic retinopathy. Ugeskr Laeger. 2018 Jul 30;180(31):V11170870. Danish. PMID: 30064622.
  33. Leasher JL, Bourne RR, Flaxman SR et al. Vision Loss Expert Group of the Global Burden of Disease Study. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care. 2016 Sep;39(9):1643-9. doi: 10.2337/dc15-2171. Erratum in: Diabetes Care. 2016 Nov;39(11):2096. PMID: 27555623. PubMed
  34. Amoaku WM, Ghanchi F, Bailey C et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020 Jun;34(Suppl 1):1-51. Erratum in: Eye (Lond). 2020 Oct;34(10):1941-1942. PMID: 32504038 PubMed
  35. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23:1084. PubMed
Annonse
Annonse